Blood-brain barrier dysfunction in multiple sclerosis: causes, consequences, and potential effects of therapies
- PMID: 38101906
- DOI: 10.1016/S1474-4422(23)00377-0
Blood-brain barrier dysfunction in multiple sclerosis: causes, consequences, and potential effects of therapies
Abstract
Established by brain endothelial cells, the blood-brain barrier (BBB) regulates the trafficking of molecules, restricts immune cell entry into the CNS, and has an active role in neurovascular coupling (the regulation of cerebral blood flow to support neuronal activity). In the early stages of multiple sclerosis, around the time of symptom onset, inflammatory BBB damage is accompanied by pathogenic immune cell infiltration into the CNS. In the later stages of multiple sclerosis, dysregulation of neurovascular coupling is associated with grey matter atrophy. Genetic and environmental factors associated with multiple sclerosis, including dietary habits, the gut microbiome, and vitamin D concentrations, might contribute directly and indirectly to brain endothelial cell dysfunction. Damage to brain endothelial cells leads to an influx of deleterious molecules into the CNS, accelerating leakage across the BBB. Potential future therapeutic approaches might help to prevent BBB damage (eg, monoclonal antibodies targeting cell adhesion molecules and fibrinogen) and help to repair BBB dysfunction (eg, mesenchymal stromal cells) in people with multiple sclerosis.
Copyright © 2024 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests BZ was supported by a joint Fonds de recherche Québec—Santé (FRQS)–Multiple Sclerosis Society of Canada fellowship. CL is an FRQS Clinicien–Chercheur Junior 2 Scholar; has served on scientific advisory boards for FIND Therapeutics, Novartis, Biogen, Sanofi, Bristol Myers Squibb, and Actelion; has served as a speaker for Novartis, Biogen, Sanofi, Roche, and EMD Serono; and has received a grant for Multiple Sclerosis Innovation from Merck–EMD Serono. AP holds the Senior Canada Research Chair in Multiple Sclerosis and active patents WO2016095046A1, US20110014183A1, and US20100310568A1.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
